ALGS Financials: Aligos Therapeutics Inc AI Analysis

Q: What are Aligos Therapeutics Inc's key financial statements?

According to the latest financial statement (Form-10K), Aligos Therapeutics Inc has a total asset of $70, Net loss of $-131

Q: What are the key financial ratios for ALGS?

Aligos Therapeutics Inc's Current ratio is 0.7, has a Net margin is -4,366.66, sales per share of $0.47.

Q: How is Aligos Therapeutics Inc's revenue broken down by segment or geography?

Currently Aligos Therapeutics Inc data is not available.

Q: Is Aligos Therapeutics Inc profitable?

no, according to the latest financial statements, Aligos Therapeutics Inc has a net loss of $-131

Q: Does Aligos Therapeutics Inc have any liabilities?

yes, Aligos Therapeutics Inc has liability of 99

Q: How many outstanding shares for Aligos Therapeutics Inc?

Aligos Therapeutics Inc has a total outstanding shares of 3.98

Home

Stock

ALGS

ALGS Financial

Aligos Therapeutics Inc

$7.38

1.93%

$0.13

As of today:Feb 10, 10:11:13 GMT-5

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

ALGS Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	2	3	15	13	4	0
Revenue Growth (YoY)	-60%	-80%	15%	225%	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	16	18	24	26	28	17
Research & Development	68	70	73	85	104	79
Operating Expenses	89	88	97	111	132	97
Other Non Operating Income (Expenses)	-1	-43	-3	0	0	-11
Pretax Income	-86	-130	-86	-95	-128	-108
Income Tax Expense	0	0	0	0	0	0
Net Income	-86	-131	-87	-96	-128	-108
Net Income Growth	13%	51%	-9%	-25%	19%	108%
Shares Outstanding (Diluted)	10.36	6.26	2.57	42.7	39.86	36.61
Shares Change (YoY)	65%	144%	-94%	7%	9%	-1%
EPS (Diluted)	-8.33	-20.94	-34.11	-2.25	-3.22	-2.97
EPS Growth	-32%	-39%	1,416%	-30%	8%	109%
Free Cash Flow	-79	-80	-79	-80	-116	-76
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	-4,300%	-2,800%	-546.66%	-746.15%	-3,200%	0%
Profit Margin	-4,300%	-4,366.66%	-580%	-738.46%	-3,200%	0%
Free Cash Flow Margin	-3,950%	-2,666.66%	-526.66%	-615.38%	-2,900%	0%
EBITDA	-86	-83	-81	-95	-125	-95
EBITDA Margin	-4,300%	-2,766.66%	-540%	-730.76%	-3,125%	0%
D&A For EBITDA	0	1	1	2	3	2
EBIT	-86	-84	-82	-97	-128	-97
EBIT Margin	-4,300%	-2,800%	-546.66%	-746.15%	-3,200%	0%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are Aligos Therapeutics Inc's key financial statements?



What are the key financial ratios for ALGS?



How is Aligos Therapeutics Inc's revenue broken down by segment or geography?



Is Aligos Therapeutics Inc profitable?



Does Aligos Therapeutics Inc have any liabilities?



How many outstanding shares for Aligos Therapeutics Inc?



Key Stats

Prev.Close

$7.24

Open

$7.24

Day's Range

$7.24 - $7.39

52 week range

$3.76 - $27.29

Volume

11.6K

Avg.Volume

75.6K

EPS (TTM)

-12.70

Dividend yield

Market Cap

$45.3M

What is ALGS?

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.



Features

AI Copilot for Stock & Crypto

Trading Strategies

Megabrain Investors Picks

Trading Mindshare